Gilead Sciences (GILD) option IV elevated, call put ratio 1 call to 1.1 puts into quarte reuslts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) PT Raised to $72 at RBC Capital
August 9, 2024 6:25 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $72.00 (from $71.00) while maintaining a Outperform rating.
The analyst comments "Core HIV and CAR-T franchises performed solidly, with improving operating leverage, a better risk profile for upcoming pipeline... More
